06:18 AM EDT, 07/21/2025 (MT Newswires) -- Sarepta Therapeutics ( SRPT ) shares extended losses in premarket trading Monday, following a plunge on Friday as the company said it will continue shipping Elevidys for the ambulant population despite a request from US Food and Drug Administration to voluntarily pause shipments.

On Friday, Sarepta said it received an informal request from the US Food and Drug Administration to voluntarily pause shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy in the US.

The company had already paused shipments for non-ambulant patients while working with the regulator to update the label and evaluate an enhanced immunosuppression regimen.

Sarepta shares fell 2.5% in recent premarket trading Monday after slumping 36% on Friday.